The aim of PROMINENT is to create a platform for precision medicine in the diagnosis and treatment of neurodegenerative disease and co-morbidities. Therefore, it will represent the first application of the platform is in Alzheimer’s disease (AD) and other dementia disorders, with scalability to other neurodegenerative diseases and beyond. The digital platform that will integrate complex, multi-modal diagnostic data and generate personalized predictions of patient-relevant outcomes and evidence-based recommendations for clinical management will also provide meaningful support to clinicians, patients, and care partners. Furthermore, it is aimed that with such platform it can be facilitated the appropriate introduction of new medical technologies (diagnostic and therapeutic innovations) and it can be provided required evidence on safety, effectiveness and cost-effectiveness for stakeholders including regulators, health technology assessment and reimbursement bodies and payers.
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility, and facilitating dovetailing with related initiatives in Europe and worldwide.
ROADMAP aims to create the conditions for an open collaboration that yields consensual and efficient uses of RWE for the benefit of Alzheimer’s Disease patients and their caregivers. This will be achieved by using pilot studies to assess methods of data integration for patient outcomes that are useful for disease modelling; and developing tools and methods for stakeholder engagement. ROADMAP will set new standards for the collation and evaluation of RWE in Alzheimer’s Disease.
AMYPAD aims at studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal ageing, through subjective cognitive decline towards mild cognitive impairment and ultimately dementia due to Alzheimer’s Disease (AD), studying the value of β-amyloid imaging as a diagnostic and therapeutic marker for AD.
EPAD aims to develop an infrastructure that efficiently enables the undertaking of adaptive, multi-arm Proof of Concept studies for early and accurate decisions on the ongoing development of drug candidates or drug combinations.